{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-26-000050","form_type":"8-K/A","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2026-07-07T20:32:48+00:00","discovered_at":"2026-07-07T20:34:00.429253+00:00","generated_at":"2026-07-07T20:34:16.060651+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Aspira Women's Health finalizes CEO Buhle separation: $200K severance, 64,583 options accelerated","bullets":["Cash severance $200,000 (6 months base salary) payable in installments; prorated $4,615.38 on July 15 payroll if signed by June 29.","Accelerated vesting of 64,583 stock options at $0.07/share, subject to Compensation Committee approval; all other unvested options forfeited.","Shares from accelerated options subject to restrictions: 90-day lock-up, daily volume limit 2,500 shares, price floor $0.45, approved broker, advance notice.","COBRA premium payments for 6 months; mutual release of claims; Buhle remains bound by confidentiality, non-solicitation, non-interference covenants.","Separation Agreement effective after 7-day revocation period (expected July 6, 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-26-000050","json":"https://secwatch.observer/filing/0000926617-26-000050.json","markdown":"https://secwatch.observer/filing/0000926617-26-000050.md","text":"https://secwatch.observer/filing/0000926617-26-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/0000926617-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/awhl-20260617x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T20:34:16.060651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d72e789f7","claim":"Michael Buhle departed as Chief Executive Officer at Aspira Women's Health Inc..","evidence_excerpt":"Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/0000926617-26-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ce50ad9f36","claim":"John (Jack) Fraser was appointed as Interim Chief Executive Officer at Aspira Women's Health Inc..","evidence_excerpt":"appointed John (Jack) Fraser as Interim Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000050/0000926617-26-000050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}